A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Status:
Completed
Trial end date:
2020-04-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug
known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborators:
Sarah Cannon Development Innovations SCRI Development Innovations, LLC